Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease

Open access
Geschwind, Michael D., Kuo, Amy L., Wong, Katherine S., Haman, Aissa, Devereux, Gillian, Raudabaugh, Benjamin J., Johnson, David Y., Torres-Chae, Charles C., Finley, Ron, Garcia, Paul, Thai, Julie N., Cheng, Hugo Q., Neuhaus, John M., Forner, Sven A., Duncan, Jacque L., Possin, Katherine L., DeArmond, Stephen J., Prusiner, Stanley B., Miller, Bruce L.·2013·Neurology

Abstract

OBJECTIVE: To determine whether oral quinacrine increases survival in sporadic Creutzfeldt-Jakob disease (sCJD). METHODS: This NIH/National Institute on Aging-funded, double-blinded, placebo-controlled, stratified randomization treatment trial was conducted at the University of California, San Francisco from February 2005 through May 2009 (ClinicalTrials.gov, NCT00183092). Subjects were randomized (50:50) to quinacrine (300 mg daily) or placebo with inpatient evaluations at baseline, and planned for months 2, 6, and 12. Subjects returning for their month-2 visit were offered open-label quinacrine. The primary outcome was survival from randomization to month 2. RESULTS: Of 425 patients referred, 69 subjects enrolled, 54 subjects were randomized to active drug or placebo, and 51 subjects with sCJD were included in survival analyses. Survival for the randomized portion of the trial (first 2 months) showed no significant difference between the 2 groups (log-rank statistic, p = 0.43; Cox proportional relative hazard = 1.43, quinacrine compared with placebo, 95% confidence interval = 0.58, 3.53). The quinacrine-treated group, however, declined less on 2 of 3 functional scales, the modified Rankin and Clinical Dementia Rating, than the placebo group during the first 2 months. CONCLUSION: This interventional study provides Class I evidence that oral quinacrine at 300 mg per day does not improve 2-month survival of patients with sCJD, compared with placebo. Importantly, this study shows that double-blinded, placebo-controlled, randomized treatment trials are possible in prion disease. Furthermore, the quantitative data collected on the course of sCJD will be useful for future trials. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that quinacrine does not improve survival for people with sCJD when given orally at a dose of 300 mg per day for 2 months.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182a9f3b4

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 175

Metadata

Authors
Geschwind, M. D., Kuo, A. L., Wong, K. S., Haman, A., Devereux, G., Raudabaugh, B. J., Johnson, D. Y., Torres-Chae, C. C., Finley, R., Garcia, P., Thai, J. N., Cheng, H. Q., Neuhaus, J. M., Forner, S. A., Duncan, J. L., Possin, K. L., DeArmond, S. J., Prusiner, S. B., & Miller, B. L.
Venue
Neurology
Published
2013-12-03
Volume
81
Issue
23
Pages
2015-2023
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2123426371
Cited by
175
References
4
FWCI
4.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182a9f3b4
The paper
Geschwind, M. D., Kuo, A. L., Wong, K. S., Haman, A., Devereux, G., Raudabaugh, B. J., Johnson, D. Y., Torres-Chae, C. C., Finley, R., Garcia, P., Thai, J. N., Cheng, H. Q., Neuhaus, J. M., Forner, S. A., Duncan, J. L., Possin, K. L., DeArmond, S. J., Prusiner, S. B., & Miller, B. L. (2013). Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. https://doi.org/10.1212/wnl.0b013e3182a9f3b4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.